Study of SGB-9768 for paroxysmal nocturnal hemoglobinuria
Part of Blood & lymphatic clinical trials.
This trial tests an experimental drug called SGB-9768 that may help people with paroxysmal nocturnal hemoglobinuria (PNH), a rare blood disorder that causes red blood cells to break down. The drug aims to control the disease and improve blood counts, which may reduce symptoms like fatigue and anemia.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 years or older.
- You must have a confirmed diagnosis of PNH with a clone size greater than 10%.
- Your average hemoglobin level must be below 100 g/L at screening.
- Your lactate dehydrogenase (LDH) level must be above 1.5 times the upper limit of normal.
- You must not have used complement inhibitors recently (or have stopped them for at least 3 months before starting the trial).
- You must be willing to receive vaccinations against certain bacterial infections before starting treatment.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new medicine, XH-S003, for people with paroxysmal nocturnal hemoglobinuria (PNH) who have not tried complement inhibitors before. The goal is to see if it can help manage symptoms like low red blood cells and fatigue.
This study tests an investigational drug called NM8074 that may help people with paroxysmal nocturnal hemoglobinuria (PNH) who still have symptoms despite being on Soliris. It aims to see if the new drug is safe and effective when added or when switching from Soliris.
This trial tests a new pill (MY008211A) for people with paroxysmal nocturnal hemoglobinuria (PNH) who still have low red blood cell counts (anemia) even after taking anti-C5 antibody therapy. The goal is to see if this new drug can raise hemoglobin levels and improve energy.
This study tests a new oral medication called MY008211A for people with PNH who have not yet tried complement inhibitors. It aims to improve anemia and reduce the need for blood transfusions by targeting the part of the immune system that destroys red blood cells.
This study tests a new medicine called VSA012 for people with paroxysmal nocturnal hemoglobinuria (PNH), a rare blood disease. The goal is to see if VSA012 can help manage symptoms like fatigue and low blood counts better than the current standard treatment.
This trial is testing an experimental pill called NTQ5082 for people with PNH who haven't been treated with complement inhibitors before. The goal is to see if it can improve anemia and control PNH symptoms like fatigue and blood clots.
Hear when a new PNH - Paroxysmal Nocturnal Hemoglobinuria trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.